How To Build Companies Based on IP: Lessons from Life Sciences and Technology Ventures
- Wharton San Francisco 2 Harrison Street San Francisco, CA, 94105 United States (map)
This panel will explore the challenges in building companies based on IP, whether it spins out of a university research lab, corporate research lab, or home grown. We'll dive into the challenges scientific or tech inventors face as they transition from researcher to entrepreneur to executive. Enterprises based on IP are increasingly facing the challenge of selecting the appropriate business model while overcoming regulatory hurdles. They also face unique challenges in how to balance keeping their IP protected while also communicating to the world what they are doing to attract customers and investors. Learn from leading investors, entrepreneurs, and institutions on how to navigate these challenges. Panel Organizer and Moderator: Deirdre Olynick, Staff Scientist, Molecular Foundry, WG' 16,
Who Should Attend:
- Entrepreneurs interested in partnering with universities or research institutions
- Investors interested in IP based companies
- Scientists or researchers interested in becoming entrepreneurs
- Companies interested in spinning out IP to partner with entrepreneurs and investors
- Tech transfer offices interested in building relationships with the entrepreneurial and investor eco-system
Working with the IPO Chief Technology Transfer Officer, Robin plans and executes strategies for industry partnerships, intellectual property management, licensing, and entrepreneurship training with the goal of accelerating the commercialization of Lab technologies. She manages Berkeley Lab’s participation in the DOE Lab-Corps program, based on the National Science Foundation’s Innovation Corps (I-Corps). Lab-Corps offers Berkeley Lab researchers tools and training to help transition energy-related technologies into products that benefit society and the national economy. Robin is building on Lab-Corps to establish a technology-to-market training program for Lab researchers as part of IPO’s broader Berkeley Lab Innovation Corps initiative.
Previously, Robin served as Director of Commercialization for the Joint BioEnergy Institute (JBEI), a DOE Lab-University consortium for developing cellulosic advanced biofuels. She developed and executed a strategic plan for technology transfer and partnerships that resulted in JBEI exceeding the top three US universities in inventions and licenses, per funding dollar. At JBEI she facilitated venture formation and negotiated partnership and licensing deals with dozens of companies, including Total Gas and Oil, Bridgestone, Abengoa, POET, COFCO, and FuturaGene.
Robin also created the Lab’s Cleantech to Market (C2M) program, which was adopted by the UC Berkeley Haas School of Business as a formal course. C2M is a partnership between students, researchers, and energy professionals to translate clean tech research into market opportunities.
Her work history includes extensive experience in conflict mediation and reporting on science, technology and the environment for The Christian Science Monitor.
B.A., Chemistry, minor in Philosophy, University of Virginia
M.S., Science, Technology, and Public Policy, George Washington University
Dr. Greg Maguire is a former professor of neuroscience and ophthalmology at the University of California, San Diego School of Medicine. His graduate training was at the University of California, Berkeley, University of Houston, University of Texas, The Marine Biological Labs, Woods Hole, MA, and Cold Spring Harbor Laboratory, NY. He was visiting associate professor of physiology at Keio University School of Medicine in Tokyo, Japan, visiting assistant professor of molecular neurobiology at the University of Washington, and a visiting scientist at Massachusetts General Hospital (MGH), at Harvard University. Awarded a prestigious Fulbright-Fogarty Fellowship from the National Institutes of Health, Dr. Maguire managed his NIH funded laboratory at UCSD studying tissue degeneration and regeneration, and the role of stem cell released molecules(SRM) through paracrine and autocrine actions to maintain, repair, and regenerate human tissues. His NIH funded studies of systems biology and reverse engineering at the University of California, Berkeley and stem cell biology at UC San Diego led to the development of adult stem cell-based S2RM technology for the development of therapeutics and medical procedures. Dr. Maguire has over 100 publications and is currently working on his book entitled, “Spontaneous Stem Cell Healing.” He is co-founder of the SRM Living Foundry at UCSD in San Diego, and is Chief Scientific Officer & Founder of BioRegenerative Sciences, Inc.
Dr. Olynick straddles the boundary between basic and applied research at Lawrence Berkeley National Laboratory. She recently graduated the Wharton School, San Francisco with a major in Entrepreneurial Management. At the Molecular Foundry, a Department of Energy Nanoscale Science Research Center, she works with industry, academic, and government R&D labs to mature state-of the-art research. In addition to R&D, her work includes technology strategy, business development, and program management. She works across technologies which include clean energy, nanobio and photonics. In addition, she works intimately with the semiconductor and storage industries to make future generation technologies a reality.
Brian manages all aspects of intellectual property including patent and trademark portfolio, patent litigation, freedom to operate, partnering and investment due diligence, patentability assessments, managing outside patent counsel and internal information flow, developing patent strategy, building value in patent assets, teaming with scientists/engineers and management on IP related goals, BD efforts, licensing, procurement and IP asset transactions.
Specialties: working closely with R&D to guide both R&D and develop IP in parallel, Experience in: electrochromic materials, controls, BOS, small molecule therapeutics, advanced materials, solar energy, semiconductor fabrication, cutting edge battery technology
J.D., Practicing Patent Practitioner since 2000
Ph.D. in Organic Chemistry, Post Doctorate with Professor Scott Denmark, 6 years industrial experience as medicinal chemist in drug design
Dr. Hammack is Chief Operations Officer, Cofounder, and a Director of EpiBiome. He received his bachelor’s degree in Electrical Engineering and Computer Science from The University of California at Berkeley, his PhD in Physics from UCSD, and was a postdoctoral fellow at LBNL. Dr. Hammack has more than 20 peer-reviewed publications in topics ranging from superfluidity, polymers, and surface chemistry to plasmonics and photonics. Before founding EpiBiome, he was a Research Staff Member at HGST where he developed nanoscale optical characterization techniques. In his current role at EpiBiome, he brings expertise in programming and data analysis, and oversees the bioinformatics program. Dr. Hammack is also an expert in microscopy and spectroscopy.